Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on October 13, 2017. The filing discloses a material corporate event regarding the departure of a senior executive and the execution of a separation agreement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and separation terms rather than financial performance metrics.
Material Changes
The primary material change is the resignation of James Fortune as Chief Operating Officer (COO) and all other officer positions, effective December 31, 2017. Key terms of the separation include:
- Transition Period: Mr. Fortune will continue to serve as COO and an at-will employee from October 13, 2017, until the Separation Date.
- Compensation During Transition: He will receive his base salary and remain eligible for company benefits plans.
- Separation Benefits:
- Continuation of base salary for 12 months post-separation.
- Payment of monthly healthcare/dental premiums for up to 12 months post-separation or until eligible for other coverage.
- Eligibility for the 2017 annual bonus if paid to active executives, calculated as if he remained employed through the payment date.
- Legal Obligations: The agreement includes a release of claims and ongoing non-solicitation, non-competition, non-disclosure, and non-disparagement obligations.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risk disclosed relates to the loss of executive leadership and the associated compensation costs outlined in the Transition Agreement.
Investor Verification Checklist
- Verify the exact Separation Date, as it may be earlier than December 31, 2017, if mutually agreed upon.
- Confirm the total cash compensation impact, including the 12-month salary continuation and potential 2017 bonus accrual.
- Review the full text of the Transition Agreement (Exhibit 10.1) for specific non-compete scope and duration.
- Monitor subsequent filings for the appointment of a replacement COO.